THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, July 07, 2021
Scipher Medicine announced positive results from a multicenter, blinded prospective observational clinical study evaluating the capabilities of the PrismRA test.
FREMONT, CA : Scipher Medicine, a precision immunology firm that matches patients with the most effective treatment, recently announced positive results from a multicenter, blinded prospective observational clinical study evaluating the capabilities of the PrismRA test to estimate which patients with rheumatoid arthritis are unlikely to respond to tumor necrosis factor-alpha inhibitor (TNFi) therapies while prescribing initial targeted therapy or during modifying treatment. PrismRA is the most widely used molecular signature test for rheumatoid arthritis treatment.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The research, published in Rheumatology and Therapy, observed that the test accurately predicted non-response to TNFi therapy in 391 targeted therapy-naive and 113 TNFi-exposed patient samples across two independent cohorts' CERTAIN cohort, a retrospective analysis, and a multicenter, blinded prospective observational clinical study, NETWORK-004.
The primary and secondary objectives of the NETWORK-004 research were satisfied, with a molecular hallmark of non-response found in 45 percent of therapy-naive patients and 40 percent of patients who had already begun TNFi therapy. According to the standard clinical result measure of ACR50 at six months (p=0.0001) and more standard endpoints of low disease activity or remissions, such as ACR70, CDAI, and DAS28-CRP at 3 and 6 months (p=0.01), patients with the signature of non-response were less likely to have a proper response to TNFi therapies than those without the signature. Providers can use patient-specific data to improve care, adjust medication, and plan future steps when they have access to precision medicine at numerous stages during care.
"The study shows PrismRA is a robust assay with wide clinical utility that can stratify patients according to their likelihood of responding to therapy," said Robert Levin, MD, of Bay Area Rheumatology in Clearwater, Florida, immediate past President of the Florida Society of Rheumatology and Affiliate Assistant Professor at the University of South Florida. "This gives providers and physicians much needed patient-specific data to guide therapy and reach their treatment targets sooner at any point in their therapeutic journey."
"Most rheumatoid arthritis patients are prescribed the world's largest selling drug class, TNFi therapy, yet the majority will not have an adequate response," said Alif Saleh, CEO Scipher Medicine. "Evidence-based tools like PrismRA will significantly improve patient outcomes and reduce wasted expense on ineffective drugs by ensuring that patients receive optimal therapy from day one."
"PrismRA helps patients who are suffering from rheumatoid arthritis find a medication that works for them more quickly," said Sarah White, PA-C, Rheumatology Associates of South Texas in San Antonio, TX. "The wait-and-see approach to therapy selection and inadequate response to therapy are two issues that make caring for rheumatoid arthritis patients difficult. PrismRA introduces precision medicine into a complex disease that hasn't had tools such as this before."
More in News